Terms: = Germ cell tumor AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Treatment
272 results:
1. Exploring fetal brain tumor glioblastoma symptom verification with self organizing maps and vulnerability data analysis.
Natarajan SK; S J; Mathivanan SK; Rajadurai H; M B BAM; Shah MA
Sci Rep; 2024 Apr; 14(1):8738. PubMed ID: 38627421
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of clinical efficacy and safety between robotic-assisted and laparoscopic adrenalectomy for pheochromocytoma: a systematic review and meta-analysis.
Wang L; Zeng W; Wu Y; Gong Z
J Robot Surg; 2024 Mar; 18(1):115. PubMed ID: 38466492
[TBL] [Abstract] [Full Text] [Related]
3. 68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results.
Waheed A; Singh B; Watts A; Kaur H; Singh H; Dhingra K; Ahuja C; Madan R; Singh A; Radotra BD
Clin Nucl Med; 2024 Apr; 49(4):e141-e148. PubMed ID: 38350065
[TBL] [Abstract] [Full Text] [Related]
4. A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [
Trautwein NF; Schwenck J; Seitz C; Seith F; Calderón E; von Beschwitz S; Singer S; Reischl G; Handgretinger R; Schäfer J; Lang P; Pichler BJ; Schulte JH; la Fougère C; Dittmann H
Theranostics; 2024; 14(3):1212-1223. PubMed ID: 38323317
[No Abstract] [Full Text] [Related]
5. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract] [Full Text] [Related]
6. PSMA PET/MR is a New Imaging Option for Identifying Glioma Recurrence and Predicting Prognosis.
Xiong M; Chen Z; Zhou C; Yang X; Hu W; Jiang Y; Zheng R; Fan W; Mou Y; Lin X
Recent Pat Anticancer Drug Discov; 2024; 19(3):383-395. PubMed ID: 38214322
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of
Mileva M; Marin G; Levillain H; Artigas C; Van Bogaert C; Marin C; Danieli R; Deleporte A; Picchia S; Stathopoulos K; Jungels C; Vanderlinden B; Paesmans M; Ameye L; Critchi G; Taraji-Schiltz L; Velghe C; Wimana Z; Bali M; Hendlisz A; Flamen P; Karfis I
J Nucl Med; 2024 Feb; 65(2):236-244. PubMed ID: 38164576
[TBL] [Abstract] [Full Text] [Related]
8. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive Stereoselectivity Assessment of Toxicokinetics, Tissue Distribution, Cytotoxicity, and Environmental Fate of Chiral Pesticide Propiconazole.
Ma S; Xin H; Zhao P; Feng S; Chen J; Yin S; Wei Y; Shi Y; Jin G; Di X; Zhang H
J Agric Food Chem; 2023 Dec; 71(49):19760-19771. PubMed ID: 38036940
[TBL] [Abstract] [Full Text] [Related]
10. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract] [Full Text] [Related]
11. Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations.
Hahn E; Chavira R; Wollenberg L; Tan W; Reddy MB
Clin Transl Sci; 2023 Dec; 16(12):2675-2686. PubMed ID: 37837178
[TBL] [Abstract] [Full Text] [Related]
12. Rural Residency Status in South Dakotans is Not Associated With More Advanced Stage Melanoma at Time of Diagnosis.
Newton J
S D Med; 2023 Sep; 76(9):401. PubMed ID: 37738489
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of two optimization algorithms (VOLO
Thiele M; Galonske K; Ernst I
J Appl Clin Med Phys; 2023 Dec; 24(12):e14144. PubMed ID: 37672349
[TBL] [Abstract] [Full Text] [Related]
14. Multi-parametric hyperpolarized
Autry AW; Vaziri S; LaFontaine M; Gordon JW; Chen HY; Kim Y; Villanueva-Meyer JE; Molinaro A; Clarke JL; Oberheim Bush NA; Xu D; Lupo JM; Larson PEZ; Vigneron DB; Chang SM; Li Y
Neuroimage Clin; 2023; 39():103501. PubMed ID: 37611371
[TBL] [Abstract] [Full Text] [Related]
15. Reduced uptake pattern on
de Jong MC; Pinto D; Parameswaran R
J Surg Oncol; 2023 Oct; 128(5):764-768. PubMed ID: 37403579
[TBL] [Abstract] [Full Text] [Related]
16. Discriminating Inflammatory Radiation-Related Changes From Early Recurrence in Patients With Glioblastomas: A Preliminary Analysis of 68 Ga-PSMA-11 PET/CT Compared With 18 F-FDOPA PET/CT.
Moreau A; Khayi F; Maureille A; Bonneville-Levard A; Larrouquere L; Ducray F; Kryza D
Clin Nucl Med; 2023 Aug; 48(8):657-666. PubMed ID: 37276534
[TBL] [Abstract] [Full Text] [Related]
17. Attention-guided multi-scale context aggregation network for multi-modal brain glioma segmentation.
Wu S; Cao Y; Li X; Liu Q; Ye Y; Liu X; Zeng L; Tian M
Med Phys; 2023 Dec; 50(12):7629-7640. PubMed ID: 37151131
[TBL] [Abstract] [Full Text] [Related]
18. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
[TBL] [Abstract] [Full Text] [Related]
19. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract] [Full Text] [Related]
20. Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.
Oldan JD; Giglio BC; Smith E; Zhao W; Bouchard DM; Ivanovic M; Lee YZ; Collichio FA; Meyers MO; Wallack DE; Abernethy-Leinwand A; Long PK; Trembath DG; Googe PB; Kowalski MH; Ivanova A; Ezzell JA; Nikolaishvili-Feinberg N; Thomas NE; Wong TZ; Ollila DW; Li Z; Moschos SJ
Oncoimmunology; 2023; 12(1):2204753. PubMed ID: 37123046
[TBL] [Abstract] [Full Text] [Related]
[Next]
